Femasys completes first in-office commercial FemaSeed infertility procedure

FEMASYS INC

First commercial procedure using FDA-cleared FemaSeed intratubal insemination performed in Saginaw, Michigan.
CEO cites FemaSeed as cost-effective, safer alternative to IVF amid Alabama Supreme Court frozen embryo ruling.
Top-line pivotal data from FemaSeed study expected to be announced in Q1 2024.
Procedure conducted by Dr. Andrew Wagner of Women's OB-GYN PC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.